Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Concludes €4M Funding Round

NEW YORK (GenomeWeb) – Finnish molecular diagnostics firm Mobidiag announced today that it has raised €4.0 million ($4.7 million) in a funding round.

Completed in less than three weeks, the funding round was led by Finnish investment service company Springvest Oy, and supported by more than 200 investors.

The new funding will help Mobidiag scale up the production of its Novodiag instruments and disposable cartridges, in addition to strengthening its global sales and marketing activities.

Mobidiag merged with Finnish firm Amplidiag and French company Genewave in 2013 to form a new entity focused on developing molecular diagnostics for infectious diseases.

"The path from the tri-party merger in 2013 to this point has been lengthy and full of challenges which we have all, one by one, successfully tackled," Mobidiag CEO Tuomas Tenkanen said in a statement.

In April, Mobidiag received CE marking for its Amplidiag CarbaR+MCR test and the Novidiag Bacterial GE+ test.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.